Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study

[1] Dowdy DW(2014)Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model J acquired immune deficiency syndromes (1999) 66 552-1399

[2] Golub JE(2015)Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral Therapy AIDS (London, England) 29 1391-248

[3] Saraceni V(2015)Predictors and outcomes of mycobacteremia among HIV-infected smear- negative presumptive tuberculosis patients in Uganda BMC Infect Dis 15 62-636

[4] Moulton LH(2014)Tuberculosis control in South Africa: successes, challenges and recommendations S Afr Med J 104 244-822

[5] Cavalcante SC(2017)Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study BMC Infect Dis 17 5-1111

[6] Cohn S(2009)Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort AIDS Lond Engl 23 631-355

[7] Pacheco AG(2015)A trial of early antiretrovirals and isoniazid preventive therapy in Africa N Engl J Med 373 808-undefined

[8] Chaisson RE(2005)Predictors of incident tuberculosis among HIV-1-infected women in Tanzania The International Journal of Tuberculosis and Lung Disease 9 1105-undefined

[9] Durovni B(2011)Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies J Acquir Immune Defic Syndr 56 349-undefined

[10] Liu E(undefined)undefined undefined undefined undefined-undefined

[1] Dowdy DW(2014)Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model J acquired immune deficiency syndromes (1999) 66 552-1399

[2] Golub JE(2015)Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral Therapy AIDS (London, England) 29 1391-248

[3] Saraceni V(2015)Predictors and outcomes of mycobacteremia among HIV-infected smear- negative presumptive tuberculosis patients in Uganda BMC Infect Dis 15 62-636

[4] Moulton LH(2014)Tuberculosis control in South Africa: successes, challenges and recommendations S Afr Med J 104 244-822

[5] Cavalcante SC(2017)Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study BMC Infect Dis 17 5-1111

[6] Cohn S(2009)Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort AIDS Lond Engl 23 631-355

[7] Pacheco AG(2015)A trial of early antiretrovirals and isoniazid preventive therapy in Africa N Engl J Med 373 808-undefined

[8] Chaisson RE(2005)Predictors of incident tuberculosis among HIV-1-infected women in Tanzania The International Journal of Tuberculosis and Lung Disease 9 1105-undefined

[9] Durovni B(2011)Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies J Acquir Immune Defic Syndr 56 349-undefined

[10] Liu E(undefined)undefined undefined undefined undefined-undefined